Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7540479rdf:typepubmed:Citationlld:pubmed
pubmed-article:7540479lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:7540479lifeskim:mentionsumls-concept:C0014257lld:lifeskim
pubmed-article:7540479lifeskim:mentionsumls-concept:C0023516lld:lifeskim
pubmed-article:7540479lifeskim:mentionsumls-concept:C0063695lld:lifeskim
pubmed-article:7540479lifeskim:mentionsumls-concept:C0007578lld:lifeskim
pubmed-article:7540479lifeskim:mentionsumls-concept:C0240903lld:lifeskim
pubmed-article:7540479lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:7540479lifeskim:mentionsumls-concept:C0205217lld:lifeskim
pubmed-article:7540479lifeskim:mentionsumls-concept:C0175630lld:lifeskim
pubmed-article:7540479pubmed:issue4lld:pubmed
pubmed-article:7540479pubmed:dateCreated1995-7-25lld:pubmed
pubmed-article:7540479pubmed:abstractTextThe aim of this study was to investigate whether levels of circulating adhesion molecules reflect vascular inflammation in rheumatoid vasculitis (RV). Levels of circulating intercellular adhesion molecule-1 (cICAM-1), c-ICAM-3 and circulating endothelial leucocyte adhesion molecule (cE-selectin) were determined in 14 patients with RV and compared to 47 patients with rheumatoid arthritis (RA) and 100 healthy donors (HD). Enzyme-linked immunosorbent assays were used to quantify cICAM-1, cICAM-3 and cE-selectin. We found that in RV significantly (P < 0.0001) elevated levels of cICAM-1 and cICAM3, but not cE-selectin, were found when compared with RA patients. Levels > 2 S.D. above the mean level of HD were present for cICAM-1, cICAM-3 and cE-selectin in 57, 71 and 21%, respectively of patients with RV and 2, 21 and 44%, respectively of the RA patients. Increased levels of both cICAM-1 and cICAM-3 were found in 43% of the RV patients and in none of the RA patients. Comparison of the serum levels of patients studied in an active and inactive phase of RV revealed significantly lower levels of cICAM-3 levels in the inactive phase. In conclusion we find that determination of cICAM-1 and cICAM-3 may be useful as a marker of vascular inflammation in patients with RV.lld:pubmed
pubmed-article:7540479pubmed:languageenglld:pubmed
pubmed-article:7540479pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7540479pubmed:citationSubsetAIMlld:pubmed
pubmed-article:7540479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7540479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7540479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7540479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7540479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7540479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7540479pubmed:statusMEDLINElld:pubmed
pubmed-article:7540479pubmed:monthAprlld:pubmed
pubmed-article:7540479pubmed:issn0263-7103lld:pubmed
pubmed-article:7540479pubmed:authorpubmed-author:MartinSSlld:pubmed
pubmed-article:7540479pubmed:authorpubmed-author:BreedveldF...lld:pubmed
pubmed-article:7540479pubmed:authorpubmed-author:ZwindermanA...lld:pubmed
pubmed-article:7540479pubmed:authorpubmed-author:Weichselbraun...lld:pubmed
pubmed-article:7540479pubmed:authorpubmed-author:VoskuylA EAElld:pubmed
pubmed-article:7540479pubmed:authorpubmed-author:MelchersLLlld:pubmed
pubmed-article:7540479pubmed:issnTypePrintlld:pubmed
pubmed-article:7540479pubmed:volume34lld:pubmed
pubmed-article:7540479pubmed:ownerNLMlld:pubmed
pubmed-article:7540479pubmed:authorsCompleteYlld:pubmed
pubmed-article:7540479pubmed:pagination311-5lld:pubmed
pubmed-article:7540479pubmed:dateRevised2008-6-13lld:pubmed
pubmed-article:7540479pubmed:meshHeadingpubmed-meshheading:7540479-...lld:pubmed
pubmed-article:7540479pubmed:meshHeadingpubmed-meshheading:7540479-...lld:pubmed
pubmed-article:7540479pubmed:meshHeadingpubmed-meshheading:7540479-...lld:pubmed
pubmed-article:7540479pubmed:meshHeadingpubmed-meshheading:7540479-...lld:pubmed
pubmed-article:7540479pubmed:meshHeadingpubmed-meshheading:7540479-...lld:pubmed
pubmed-article:7540479pubmed:meshHeadingpubmed-meshheading:7540479-...lld:pubmed
pubmed-article:7540479pubmed:meshHeadingpubmed-meshheading:7540479-...lld:pubmed
pubmed-article:7540479pubmed:meshHeadingpubmed-meshheading:7540479-...lld:pubmed
pubmed-article:7540479pubmed:meshHeadingpubmed-meshheading:7540479-...lld:pubmed
pubmed-article:7540479pubmed:meshHeadingpubmed-meshheading:7540479-...lld:pubmed
pubmed-article:7540479pubmed:meshHeadingpubmed-meshheading:7540479-...lld:pubmed
pubmed-article:7540479pubmed:meshHeadingpubmed-meshheading:7540479-...lld:pubmed
pubmed-article:7540479pubmed:meshHeadingpubmed-meshheading:7540479-...lld:pubmed
pubmed-article:7540479pubmed:meshHeadingpubmed-meshheading:7540479-...lld:pubmed
pubmed-article:7540479pubmed:year1995lld:pubmed
pubmed-article:7540479pubmed:articleTitleLevels of circulating intercellular adhesion molecule-1 and -3 but not circulating endothelial leucocyte adhesion molecule are increased in patients with rheumatoid vasculitis.lld:pubmed
pubmed-article:7540479pubmed:affiliationDepartment of Rheumatology, University Hospital, Leiden, The Netherlands.lld:pubmed
pubmed-article:7540479pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7540479pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:7540479pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7540479lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7540479lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7540479lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7540479lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7540479lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7540479lld:pubmed